MethodPDF Available

[DEPRECATED] v3.31 Specifications for: Rapid Testing of HASD CFS/ME Disease Model

Authors:

Abstract

[v3.31 18th June 2021] Changelog: 1. Stopped feeding infected cells, per v1.x, v2.x. 2. Disabled virally induced protein expression alterations (GLS1 - KGA, GAC and GLUD1, GLUD2). 3. Induced spontaneous, selective apoptosis in latent and lytic cells. 4. Improved ROS management. 5. Clarified dietary concepts, which are required to reduce mTOR and allow latent cell apoptosis. 6. EGCG dose significantly increased to allow sufficient reduction / balance of GDH without simultaneous use of spironolactone, which significantly reduces GDH via anti-androgenic functions. 7. Sulforaphane, Retinoic acid, boron and Vitamin D3’s role in stabilising hormonal influences of GDH included. 8. L-ornithine L-aspartate reintroduced as a nitrogen disposal option during the induction phase “4 day crash”, with / without sodium benzoate. 9. Forskolin added for improved cAMP and beta-oxidation, also helping to normalise catecholamines, GDH. 10. Lab-tested various reishi products. Currently “Life Extension Reishi Complex” is the only compatible product. [2021-06-24 UPDATE: ONGOING RESEARCH INTO (CO-)INFECTIONS HAS INDICATED COXSACKIE B FAMILY AS A POSSIBLE CONTRAINDICATION, DUE TO ANTIBODIES FOR GLUTAMATE DECARBOXYLASE AND WILL BE REFLECTED IN THE NEXT RELEASE, IF CONFIRMED. "EARLY WARNING SIGNS" MAY INCLUDE: LOW FSH (<1.8IU/L, MALES) STIFF PERSON SYNDROME, INCLUDING NECK (GAD ANTIBODIES, or SEROPOSITIVE FOR COXSACKIE / OTHER ENTEROVIRUS)]
Internal use only - not for distribution.
Specifications for:
Rapid Testing of HASD CFS/ME Disease Model
[v3.31 18th June 2021]
Changelog:
1. Stopped feeding infected cells, per v1.x, v2.x.
2. Disabled virally induced protein expression alterations (GLS1 - KGA, GAC and GLUD1, GLUD2).
3. Induced spontaneous, selective apoptosis in latent and lytic cells.
4. Improved ROS management.
5. Clarified dietary concepts, which are required to reduce mTOR and allow latent cell apoptosis.
6. EGCG dose significantly increased to allow sufficient reduction / balance of GDH without simultaneous use of
spironolactone, which significantly reduces GDH via anti-androgenic functions.
7. Sulforaphane, Retinoic acid, boron and Vitamin D3’s role in stabilising hormonal influences of GDH included.
8. L-ornithine L-aspartate reintroduced as a nitrogen disposal option during the induction phase “4 day crash”,
with / without sodium benzoate.
9. Forskolin added for improved cAMP and beta-oxidation, also helping to normalise catecholamines, GDH.
10. Lab-tested various reishi products. Currently “Life Extension Reishi Complex” is the only compatible product.
Scope of Application -
1. Participant screening
Inclusion criteria:
(Seropositive for any one or more)
Exclusion criteria:
(Excluded by positive result)
EBV++
(For lytic detection, ref: “EBV Lytic Phase”)
Clostridium difficile
(untested - ref: “Roadmap”)
CMV++
Chlamydia-pneumoniae
(untested - ref: “Roadmap”)
HHV-6++
Borrelia burgdorferi
(untested - ref: “Roadmap”)
HHV-7++
2. Purpose
Induced selective apoptosis of infected cells and correction of negative metabolic
alterations by HHV infection.
3. Physician Approval Required
Where other diseases / disorders exist or other medications are prescribed, refer to a
physician for further advice.
[page 1 of 12]
Responses To Participant Questionnaire
Name_____________________________________
Date____________________
1. Do you have sensory hypersensitivity (feel strong discomfort and/or experience PEM from
exposure to moderately loud sounds or bright lights)?
________________________________________________________________________
2. Do you have cognitive impairment (problems with concentration and/or memory)?
_________________________________________________________________________
3. Do you have insomnia or unstable circadian rhythm?
_________________________________________________________________________
4. Do you have orthostatic issues (POTS, orthostatic hypotension, vasovagal syndrome)?
_________________________________________________________________________
5. Do you have issues with extreme temperatures (easily get too cold or too hot)?
_________________________________________________________________________
6. How long do you spend in bed each day?
_________________________________________________________________________
7. Do you consent to anonymised personal data relating to your medical history and
participation being shared and/or published with others?
_________________________________________________________________________
[If YES, retain complete section “Record of a participant’s consent to publication of images
and/or information about them in reports or journals.”]
[page 2 of 12]
Phase One (optional) - GDH knock-down water-fasting
This is a non-immunological method for inducing apoptosis in latent and lytic cells and is
described on pages 23, 24 onwards in “CFS/ME - A New Hope.”
This process is carried out for a minimum of 3 days and is reported in the literature to also
help rebuild a compromised immune system. For this reason, participants who implement
Phase One will be expected to experience a delayed intense immune response when
entering Phase Two.
This method utilises metabolic differences between uninfected cells and infected cells to
cause selective apoptosis in infected cells, while stimulating high tissue regeneration rates
and levels of growth hormone.
Tissue losses of approximately 1lb / day would be expected (plus losses of retained water,
food-in-transit.)
The described enhancements to a standard water-fast are expected to significantly increase
selective viral apoptosis, compared to a standard water-fast.
Important safety considerations are also described in the referred document.
Intense symptoms of nausea, diarrhoea and inflammation in infected tissues may be
expected.
This method should be conducted under appropriate supervision.
Participants who implement Phase One may skip the first 4 days of extra-low carb dietary
alteration in Phase Two.
[page 3 of 12]
Phase Two - Management
Dietary
Intervention
Purpose
AM
Noon
PM
Evening
Sodium Benzoate
and/or
+Nitrogen disposal
1000mg
(Days 1-4)
1000mg
(Days 1-4)
1000mg
(Days 1-4)
1000mg
(Days 1-4)
L-Orninthine
L-Aspartate
+Nitrogen disposal
+GABA
250mg+
(Days 1-4)
250mg+
(Days 1-4)
250mg+
(Days 1-4)
500mg+
(Days 1-4)
Life Extension Mix
(contains EGCG, E,
Bs, many others)
-GDH, etc
+Methylation
3 capsules
3 capsules
3 capsules
3 capsules
Additional EGCG
-GDH, -ROS
150mg+
150mg+
150mg+
Life Extension Reishi
Complex
(Cannot substitute)
-CtBP, -NF-κB
+SIRT4, -GDH
+Viral apoptosis
2 capsules
2 capsules
2 capsules
Lion’s Mane
Beta-glucans
+Viral apoptosis
250mg+
250mg+
250mg+
[Beta-glucan
content in mg]
Oat Bran
Beta-glucans
+Viral apoptosis
+Bile flow
15g+
15g+
15g+
[Approx 1000mg
beta-glucans+]
R-ALA
-ROS
+Chelation
300mg+
300mg+
300mg+
300mg+
NAC
-ROS (via GSH)
+Acetyl-CoA
1000mg+
1000mg+
1000mg+
1000mg+
Vitamin C
Vitality C
-ROS
1 serving
Liposomal
Glutathione
-ROS
500mg
500mg
500mg
[sublingual,
between meals]
Choline
Total of 500mg choline
+Liver
+Acetylcholine
250mg
250mg
250mg
Forskolin
+cAMP
10mg (active)
10mg (active)
10mg (active)
Vitamin D3
+Serum 25(OH)D
5000-10000IU
[Target: 120-180
nmol/l]
A high-dose
“loading phase”
can also be
utilised, where.
Melatonin
+α-KG disposal
+Sleep
300mcg
Creatine
Monohydrate
ATP regeneration
3g
3g
Glycine
-ROS (via GSH)
+Collagen
5g
5g
5g
5g
Taurine
+Sleep, GABA
2000mg+
Probiotic
InnovixLabs
Multi-Strain Probiotic,
50 Billion
+Microbiome
+Prebiotic
1 capsule
Prebiotic
Now Foods NutraFlora
FOS, Pure Powder
+Microbiome
+Prebiotic
5g
5g
[page 4 of 12]
Daily Macros
Net carbs: Starting at
50-85g for first 4 days,
low GI
Proteins: >1.8g/kg
Fats: >2g/kg as
calorific lever
+Aspartate
+Precursor to
acetylcholine, etc
+Microbiome
1 egg
or meat
Resistant starch
+ spoonful of
dairy
>750ml water
1 large egg
or meat
Resistant starch
+ spoonful of
rice
>750ml water
1 large egg
or meat
Resistant starch
+ spoonful of
potatoes
>750ml water
1 large egg
or meat
Resistant starch
+ spoonful of
tofu / soy
>750ml water
The intention is to create a “CFS friendly” highly nutritious, gut microbiome enhancing diet,
as described in our second paper.
Liver and muscle glycogen is intended to be maintained above inducing ketosis - slowly
increase low-GI carbs, as necessary. Essential fatty acids are maintained.
Identifying and maintaining energy balance:
By administering EGCG and Reishi triterpenes, key viral alterations to energy homeostasis
are disabled. This means that energy is no longer being “pushed” into the mitochondrial
reactions from alpha-ketoglutarate<-glutamate<-glutamine or with high ROS / hypoxia,
transamination with aspartate/oxaloacetate. This reduces or eliminates causal factors for
“Post-Exercise Malaise” (PEM) and many other symptoms.
When commencing the treatment plan, the intent is to rapidly reduce / normalise ROS and
restore the mitochondrial energy balance to normal operating parameters. Excess energy
will create ROS and under most circumstances, create additional glutamate to metabolise
and balance against endogenous GABA, also leading to PEM / excess urea formation.
This means generally avoiding dramatic elevations of blood glucose and excessive amounts
of specific supplements (eg. succinate, B12 vitamin, etc) which “push” energy into the
mitochondria via anaplerosis, and/or other supplements that adversely alter energy input
surrounding pyruvate metabolism (eg. iodine, resveratrol).
Unless intentionally consuming a ketogenic diet, glycogen levels need to be maintained, to
prevent causing undue fatigue. This requires sufficient daily intake of low-GI carbohydrates
and optimally consumed as an increased number of small meals to avoid insulin spikes.
Glycogen requirements will vary based on activity levels and liver function, each day. As the
viral alterations are wound back, daily carbohydrate intake will need to increase to an
appropriate balancing level, where sufficient glycogen is maintained. If this is not maintained,
extreme fatigue and dizziness will be noticed, along with hunger. Cortisol levels may
increase at these times, needed for gluconeogenesis, further causing unnecessary anxiety.
Once the oxidative stress is normalised and viral alterations are disabled, a target daily (net,
low-GI) carbohydrate intake may exceed 1.5-2g per kg of bodyweight, depending on activity
levels. Excess carbs may cause PEM.
Dietary protein intake also needs to adequately maintain amino acid levels, without being
excessive, thereby generating undue nitrogen waste.
[page 5 of 12]
At specific times, energy derived from fatty acid oxidation may be impaired, leading to
“hypoglycemic” episodes - dizziness, confusion, postprandial fatigue, waking fatigue. This
may be confounded by similar symptoms induced by intense immune response.
This can also be observed during or following periods of low-activity, if nitrogen excretion
becomes excessive, depleting acetyl-CoA and also during any acute hepatic immune
response periods. This impaired ability to obtain energy derived from fat may resemble
type-2 diabetes. The melatonin synthesis pathway can become impaired with acetyl-CoA
depletion.
If a participant experiences episodic hypoglycemia symptoms, these may be prevented by:
1. Increasing the total daily amount of low-GI carbs to help refill glycogen.
2. Increase the total daily protein intake.
NB. 25-50mg of succinate and/or 10-15g of glucose can be occasionally administered during
a hypoglycemic episode, to assist recovery.
Participants are advised to maintain their “optimal range” of daily macronutrient intakes and
also “appropriate”, “paced” exercise levels, to avoid creating high levels of ROS and
concomitant nitrogen waste.
Key Dietary Parameters
1. High fat, low (net) carb, low GI, moderate-high protein.
2. Includes amylose starch (resistant starch) - small amounts of unripe banana, oat bran,
wheat bran (oat bran already in the supplement schedule).
3. Moderate-high fructooligosaccharides (FOS) - onion, garlic, blue agave, yacon root, leeks,
chicory root, Jerusalem artichokes, asparagus, bananas (if tolerable). (FOS already in the
supplement schedule)
4. Array of coloured vegetables & berries, etc.
5. “Some” butter is encouraged for additional butyric acid. This will enhance immune
response.
6. Total daily electrolyte targets.
These recommendations are elemental totals from all sources - combined food, drugs and
supplements.
(eg. magnesium citrate, sodium chloride, sodium benzoate, potassium chloride, potatoes,
spinach, broccoli, casein.)
Sodium 1500-2000mg
Potassium 3500-5000mg
Magnesium 750-1250mg
Calcium 1000-2000mg
Hydration
>3.5L of water a day. (NB. This is critical.)
Example Diet Plan - (Also critical, see page 8)
[page 6 of 12]
[page 7 of 12]
Protocol Implementation
NB. Due to the nature of the disorder a specific introduction sequence of 3 stages is
required. Failing to adhere to these stages may cause additional nitrogen and lactate burden
to occur, inducing encephalopathy and avoidable days of further suffering.
1. YELLOW SECTION
[SODIUM BENZOATE and/or L-ORNITHINE L-ASPARTATE]
Benefits: Provides low-cost metabolism and excretion path for temporary
ammonia burden.
Expectations: The first 4 days of introducing reishi (Section 2) and correcting the
mitochondrial dysfunction is expected to induce significant metabolic processing,
as a backlog of ammonia is released.
Proportional to the elevation of systemic nitrogen, by restoring the purine
nucleotide cycle, some temporary and sometimes very unpleasant effects may be
experienced during this corrective stage, such as head pressure, hot hands,
weakness, PEM. This is reported to last approximately 4 days.
2. GREEN SECTION
[EGCG, TRITERPENES, BETA GLUCANS, R-ALA, Liposomal Glutathione,
Glycine, Vitamins B, C, E, Choline, Forksolin, Melatonin]
Benefits: Disables viral alterations and induces selective apoptosis, while
providing some moderate improvements to mitochondrial efficiency. Reduces
lactate, ROS and nitrogen load via exosomes, with sleep benefits.
Expectations: This section normally induces significant temporary metabolic
processing (see Section 1).
Intense immune reactions are expected, when adding beta-glucans to reishi
triterpenes. Flu symptoms, inflammation / pains, fever, rashes, fever, dizziness,
intense fatigue, etc.
NB. Discontinuing reishi for any period will result in a repeat of these 4 days,
if/when reintroduced. Not recommended.
Method: Introduce all components. Lion’s Mane, Oat bran can be paused /
restarted with tolerance to immune response, fatigue, dizziness.
3. ORANGE SECTION
[Dietary Parameters]
Benefits: provides the benefits of a functional, nutritious diet. Provides microbiome
alterations to reduce reliance on supplements.
[page 8 of 12]
Expectations: some temporary gas, cramping and GI upset may be initially
noticed during the microbiome adaptations and gall bladder remediation.
This has been reported to persist for 2-3 weeks.
Method: Introduce the food changes first, then add the pre/probiotics.
Daily Tasks
Monitor blood pressure (BP) and maintain a morning resting target of approximately 110/70.
Adjust sodium intake up if BP <85/##, adjust sodium down if BP >135/90.
Any headaches should be treated with 300mcg melatonin and a nap. Report as “possible
urea elevation.”
Log previous day’s step count.
Log date, any dosing variance to previous day’s schedule and any observations.
Check for “liver pressure / pain” - this may be an early indication of hepatic immune
response.
Optimal sleep patterns are required for nightly metabolite cleanup and this should be
focused on achieving / maintaining.
NB. During episodes of acute hepatic / neural immune response, significant energy
deficit / drowsiness and flu-like symptoms, etc. may occur, which may resemble
“mono”. This could be expected to last 2 weeks, or longer and should be managed
like an initial EBV infection - participants are recommended bed-rest and to avoid
exercise.
Contraindications
1. NAD+ or NADH related supplements (although NAD+ precursors may be useful during
days 1-4, being tested). These may upset NAD+:NADH ratio and alter glutamate
homeostasis.
2. Tylenol.
3. Serum D3 insufficiency. This will impair immune response capabilities. Sufficiency defined
as >70nmol/L, with a therapeutic level of 120-180 nmol/L suggested as optimal.
4. Gabapentin, pregabalin. Simultaneous use of these medications may increase GDH and
prevent symptomatic relief. (Testing: EGCG at 200mg+ to accommodate this.)
*Known Limitations*
ACV, amylose starch and FOS may induce temporary GI distress / gas / bloating during
microbiome adaptations.
Benzodiazepine users may experience challenges with existing dose appropriateness.
Solutions to this are being explored.
Roadmap
TBC
[page 9 of 12]
Record of a participant’s consent to publication of images
and/or information about them in reports or journals.
Name of participant:
Relationship to participant
(if participant not
signing this form):
Description of the photo,
image, text or
other material (Material)
about the
participant. A copy of the
Material must be
attached to this form:
Provisional title of article in
which Material
will be included:
CONSENT FORM
I_________________________________________ [PRINT FULL NAME]
give my consent for the Material about [me/the participant] to appear in a publication.
I confirm that I: (please tick boxes to confirm)
have seen the photo, image, text or other material about me/the participant
have read the report or article to be published
am legally entitled to give this consent.
I understand the following:
(1) The Material will be published without my/the participant’s name attached,
however I understand that complete anonymity cannot be guaranteed. It is possible
that somebody somewhere - for example, somebody who looked after [me/the
participant] or a relative - may recognise [me/the participant.]
(2) The Material may show or include details of my/the participant’s medical condition
or injury and any prognosis, treatment or surgery that I have/the participant has, had
or may have in the future.
(3) The article may be published in a journal which is distributed worldwide. These
publications go mainly to doctors and other healthcare professionals but are also
seen by many others including academics, students and journalists.
[page 10 of 12]
(4) The article, including the Material, may be the subject of a press release, and may
be linked to from social media and/or used in other promotional activities. Once
published, the article will be placed on a journal website and may also be available on
other websites.
(5) The text of the article will be edited for style, grammar and consistency before
publication.
(6) [I/the participant] will not receive any financial benefit from publication of the
article.
(7) The article may also be used in full or in part in other publications and products
published by the publisher and/or by other publishers. This includes publication in
English and in translation, in print, in digital formats, and in any other formats that
may be used now and in the future. The article may appear in local editions of
journals or other publications, published worldwide.
(8) I can revoke my consent at any time before publication, but once the article has
been committed to publication (“gone to press”) it will not be possible to revoke the
consent.
(9) This consent form will be retained securely and in confidence by Thinking Muscle
and any publisher, in accordance with the law, for no longer than necessary. Personal
data provided in this form will be used and retained in accordance with our Privacy
Policy available at https://www.thinkingmuscle.com/privacy/.
Please tick box to confirm the following:
Where this consent relates to an article in any published journal, [I have/the
participant has] had the opportunity to comment on the article and I am satisfied that
the comments, if any, have been reflected in the article.
Signed:
____________________________
Print name:
_______________________________
Address:
___________________________________
Email address:
______________________________
___________________________________
Telephone no:
_______________________________
If signing on behalf of the participant, please give the reason why the participant can’t
consent for themselves (e.g. participant is under 18 or has cognitive or intellectual
impairment).
_________________________________________________________________________
Date: __________________________
[page 11 of 12]
If you are signing for a family or other group, please tick the box to confirm
that all relevant members of the family or group have been informed.
If the participant is under the age of 18 but has sufficient understanding of the
consent process and its implications, they must also confirm their agreement:
Signed:__________________________
Print name:_________________________
Date of birth: ____________________
Date:______________________________
Details of the person who has explained and administered the form to the participant
or their representative (e.g. the corresponding author or other person who has the
authority to obtain consent).
Signed:___________________________
Print name:__________________________
Position:
___________________________
Institution:
_________________________________
_________________________________
Address:____________________________
____________________________________
____________________________________
Email address:
_________________________________
Telephone no:_____________________
Date: _____________________________
[page 12 of 12]
ResearchGate has not been able to resolve any citations for this publication.
ResearchGate has not been able to resolve any references for this publication.